WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES

Checking

 

Medtronic plc MDT

NYSEMedical devicesFinancials to Jul 31, 2026 · Updated Nov 11, 2026

On Stock Analysis · affiliate link
MDT financials
Moat score
58
ROIC
8.0%
P/E
–
EV/EBIT
–
FCF yield
–
Dividend yield
–
Market cap
–

Moat ranks

Score rankTied #327 of 396
Durabilitymedium
Market structureOligopoly
Pricing powermoderate

Balance sheet

7/31/26
$BApr 24Jul 31
Cash1.91.7
Securities7.37.1
Debt27.928.2
Net cash-18.6-19.3
Equity49.550.2
Leverage
Debt / EBITDA
2.89×
Debt / equity
0.56×
Leases (4/24/26)
$1.2B
Capital
Diluted shares
1,285M
Book value / share
$39.09
Price / book
–
Net cash / share
−$15.02
Market cap
–
Enterprise value
–

Per-share record

Fiscal years and TTM
Scale
$0$10$20$30'17'18'19'20'21'22'23'24'2528.23'2629.21TTM
Revenue per shareCash flow per share

Key indicators

Latest: Q1 '27
IndicatorLatestVs year agoLast 8 quarters
Revenue growth13.7%+5.4 pts
Operating margin18.1%+1.2 pts
FCF margin13.2%+6.4 pts
Capex / revenue5.2%-0.7 pts
Global CGM attachment rate69.0%+5.0 pts
Cardiac Ablation Solutions revenue growth+88%+38 pts
New insulin pumps sold (quarter)~34,000+6%
Cranial and Spinal Technologies revenue (quarter)$1.4B+13%
Surgical and Endoscopy revenue (quarter)$1.7B+9%

Margins and growth from reported quarters; company KPIs as reported in results releases.

About MDT

Medtronic sells cardiac implants and ablation tools, spine and neurosurgical platforms, surgical instruments and monitoring devices. Clinical training, connected workflows and installed-system consumables provide selective protection.

Revenue mix
Cardiovascular Portfolio 42.0%Neuroscience Portfolio 30.9%Medical Surgical Portfolio 26.5%Former Diabetes / MiniMed (separated October 2026) 0.0%
  • Data Workflow Lockin

    Implanted cardiac devices and remote monitoring put Medtronic in repeated clinic workflows.

  • Training Org Change Costs

    Physicians and lab staff learn Medtronic catheters, mapping software and procedure protocols.

  • Training Org Change Costs

    Surgeons and operating-room teams learn Medtronic imaging, navigation, robotic guidance and implants together.

  • Data Workflow Lockin

    AiBLE connects planning, imaging, navigation and robotic guidance in the operating room.

Timeline
  1. Oct 15, 2026

    Medtronic completed the MiniMed split-off and retains no ownership. Removed former Diabetes moat claims from current scoring and rebased retained-portfolio revenue weights on FY2026 reported sales; retained historical financial/KPI scope pending issuer recast.

  2. Oct 7, 2026

    Medtronic published a final exchange ratio of 4.5939 MiniMed shares per accepted Medtronic share, with the upper limit in effect. The cap reduces the pricing incentive; completion and Medtronic shares retired remain pending before the scheduled October 9 expiry.

  3. Oct 1, 2026

    Medtronic announced Category I procedure-code approvals for Altaviva and Symplicity, effective January 2028. Codes support payment pathways but do not guarantee coverage.

  4. Sep 30, 2026

    Medtronic announced Affera mapping software clearances and a PulseSelect proximity-software CE Mark, expanding ablation workflow capabilities.

  5. Sep 24, 2026

    Medtronic recalled SmartSync/CareLink products in Canada for a Micra remaining-life calculation error, adding a cardiac software remediation need.

Financial record

Fiscal year2017201820192020202120222023202420252026TTMTrendChange 2017–26
Per share ($)
Revenue21.3521.8922.5121.4022.2423.4523.4324.3326.0028.2329.21+3.2%/yr
Cash flow4.943.425.165.354.615.444.535.105.465.696.25+1.6%/yr
Earnings2.892.273.413.542.663.732.822.763.613.734.07+2.8%/yr
Free cash flow4.042.644.334.463.614.423.443.914.024.214.77+0.5%/yr
Capex0.900.780.840.901.001.011.091.191.441.481.48+5.7%/yr
Dividends1.711.821.982.142.302.502.712.762.782.832.84+5.8%/yr
Book value36.0837.0736.9037.5537.9838.8938.6337.7537.2338.4039.09+0.7%/yr
Diluted shares (M)1,3911,3681,3581,3511,3541,3511,3331,3301,2901,2881,285-0.9%/yr
Totals ($B)
Revenue29.730.030.628.930.131.731.232.433.536.437.5+2.3%/yr
Operating income5.46.66.34.84.55.85.55.16.06.56.8+2.1%/yr
Net income4.03.14.64.83.65.03.83.74.74.85.2+2.0%/yr
Free cash flow5.63.65.96.04.96.04.65.25.25.46.1-0.4%/yr
Buybacks3.52.22.91.30.72.50.62.13.21.01.2-12.8%/yr
Dividends2.42.52.72.93.13.43.63.73.63.63.7+4.9%/yr
Net cash-19.6-14.3-15.4-13.8-15.5-13.4-16.3-16.9-19.5-18.6-19.3+$0.9B
Margins & returns (%)
Gross margin68.769.870.067.465.268.065.765.365.365.065.0-3.7 pts
Operating margin18.122.220.516.614.918.217.615.917.817.818.1-0.3 pts
Net margin13.610.415.216.612.015.912.011.413.913.213.9-0.4 pts
FCF margin18.912.119.220.816.218.914.716.115.514.916.3-4.0 pts
ROIC6.38.37.86.15.57.16.66.37.27.88.0+1.5 pts
Return on equity8.06.19.29.47.09.67.37.39.79.710.4+1.7 pts
R&D % of revenue7.47.57.68.18.38.78.68.58.17.97.8+0.5 pts
Stock pay % of revenue1.21.10.91.01.11.11.11.21.31.31.3+0.1 pts
Capex % of revenue4.23.63.74.24.54.34.74.95.55.25.1+1.0 pts

Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.

TTM = four quarters to Jul 31, 2026. Per-share values use diluted weighted shares.ROIC = operating income × (1 − 18.1% tax rate, the company's own over three fiscal years excluding one-offs) ÷ (equity + debt − cash and current securities). Returns show a dash when their base is negative or under 10% of revenue. Free cash flow = operating cash flow − capex. Debt is all borrowings; net cash counts long-term securities and excludes leases.

Moat

Moat scorecard

Moat score58
Strength
Confidence
Structure
Oligopoly
Durability
medium
Trajectory
stable
Pricing power
moderate
Segments
  • Cardiovascular Portfolio42.0%
    2 claims
  • Neuroscience Portfolio30.9%
    2 claims
  • Medical Surgical Portfolio26.5%
    1 claim
  • Former Diabetes / MiniMed (separated October 2026)0.0%
    No moat

Moat claims

Applies to
Cardiovascular Portfolio
Confidence
Durability
medium
Trajectory
stableas of Oct 7, 2026
Why it holds

Implanted cardiac devices and remote monitoring put Medtronic in repeated clinic workflows. Replacing a monitoring vendor requires staff changes and patient transfer; it does not make future implants exclusive. Software reliability is part of the protection.

Why stable

Remote monitoring remains embedded, but the CareLink software recall shows that installed use also creates quality obligations. No public clinic-retention series shows wider protection.

Indicators
  • Cardiac Rhythm and Heart Failure revenue (fiscal year)$7.5B+17%
  • Cardiac Rhythm and Heart Failure revenue (quarter)$2.1B+22%
  • Electrophysiology Therapies revenue (quarter)$2.2B+30%
Risks
  • Vendor-neutral monitoring platforms and interoperability requirements
  • Cybersecurity incidents reducing adoption of connected services
  • Errors in battery-life estimates can damage clinical trust and require software corrections.

Profile change log

  1. Nov 11, 2026 · business change

    Medtronic completed the MiniMed split-off and retains no ownership. Removed former Diabetes moat claims from current scoring and rebased retained-portfolio revenue weights on FY2026 reported sales; retained historical financial/KPI scope pending issuer recast.

  2. Oct 8, 2026 · analyst revision

    Corrected the ventilator exit decision date to February 20, 2024, from a month-only date. The annual filing states the exact decision day.

  3. Oct 8, 2026 · business change

    MiniMed amended its Abbott agreement to add dual glucose-ketone sensors for exclusive integration with its smart dosing systems. The seven-year supply term supports the product pipeline but adds purchase and supplier obligations.

  4. Oct 8, 2026 · analyst revision

    Clarified Abbott sensor compatibility: a seven-year agreement makes Abbott the exclusive third-party sensor supplier for certain MiniMed systems and restricts competing sensor purchases. Added this supplier dependence without changing moat strength or segment evidence status.

  5. Oct 7, 2026 · business change

    Medtronic published a final exchange ratio of 4.5939 MiniMed shares per accepted Medtronic share, with the upper limit in effect. The cap reduces the pricing incentive; completion and Medtronic shares retired remain pending before the scheduled October 9 expiry.

  6. Oct 7, 2026 · business change

    FDA published pediatric postmarket review questions identifying no new safety signals for the Activa Dystonia and Contegra devices and recommending continued routine monitoring. The finding covers those selected devices and is not a portfolio-wide safety conclusion.

  7. Oct 7, 2026 · analyst revision

    Removed combined leader lists from the broad neurological and specialist-device markets because their sources cover different products. Added 2025 worldwide spine concentration and selected FDA pediatric safety reviews without treating either as evidence for the whole portfolio.

  8. Oct 7, 2026 · analyst revision

    Restricted each debate argument to the facts supported by its linked source. Competing robot and spine platforms remain in separate sourced arguments; later-quarter ablation growth and the Cornerstone investment remain in their own records.

  9. Oct 7, 2026 · analyst revision

    Corrected the Bravo timeline to the FDA notice publication date. The source confirms Class I status but does not date the classification decision. Removed repeated recall risk from the debate and kept the cardiac software recall in its claim and market evidence.

  10. Oct 7, 2026 · analyst revision

    Added surviving Blackstone payment guarantees to the separation debate. Selling MiniMed equity does not by itself eliminate all contingent Medtronic cash obligations.

  11. Oct 7, 2026 · business change

    Medtronic recalled certain Harmony valve delivery-catheter lots after tip-detachment risk was found. Retrieval or surgery can be needed during implantation; successfully implanted valves are unaffected.

  12. Oct 7, 2026 · analyst revision

    Changed the spine software and Hugo consumables trajectories from widening to stable. New rival evidence shows competing integrated systems; Medtronic does not yet publish the recurring-use measures needed to establish wider protection. Strength and segment evidence status are unchanged.

  13. Oct 7, 2026 · analyst revision

    Kept estimate-driven tax benefits in reported earnings and added the specific FY2018 intercompany-IP tax benefit. Updated the Puerto Rico tax-case status to the unresolved remand and separated post-July strategic investments from historical acquisition cash flows.

  14. Oct 7, 2026 · business change

    Medtronic announced up to $80 million of Pi-Cardia investments, expected exclusive ShortCut distribution in 2027 and a conditional acquisition option for complex valve procedures.

  15. Oct 7, 2026 · business change

    Medtronic announced its Cornerstone Robotics partnership and paid about $700 million in Q2 FY2027 for a strategic investment and non-U.S. distribution rights.

  16. Oct 7, 2026 · business change

    Medtronic announced Category I procedure-code approvals for Altaviva and Symplicity, effective January 2028. Codes support payment pathways but do not guarantee coverage.

  17. Oct 7, 2026 · business change

    Medtronic announced Affera mapping software clearances and a PulseSelect proximity-software CE Mark, expanding ablation workflow capabilities.

  18. Oct 7, 2026 · business change

    Medtronic recalled SmartSync/CareLink products in Canada for a Micra remaining-life calculation error, adding a cardiac software remediation need.

  19. Oct 7, 2026 · business change

    Medtronic announced FDA clearance of LigaSure RAS Maryland on Hugo, broadening U.S. robotic procedure instruments.

  20. Oct 7, 2026 · business change

    FDA published a Class I recall notice for Bravo capsule delivery devices on September 15. Affected products must be removed and replaced; the notice reports 184 serious injuries and no deaths as of August 10.

  21. Oct 7, 2026 · business change

    Medtronic launched the MiniMed share-exchange offer to complete separation; the October 9 scheduled expiry remained pending.

  22. Oct 7, 2026 · business change

    Medtronic raised FY2027 organic revenue growth guidance to 7.25%-7.75% after its extra-week first quarter.

  23. Oct 7, 2026 · business change

    Medtronic completed the SPR Therapeutics acquisition, adding temporary peripheral nerve stimulation for pain treatment.

  24. Oct 7, 2026 · business change

    Medtronic completed the Scientia Vascular acquisition, adding neurovascular access tools to its therapeutic portfolio.

  25. Oct 7, 2026 · business change

    Medtronic acquired the remaining CathWorks stake, adding wire-free coronary assessment to its cardiovascular portfolio.

  26. Oct 7, 2026 · business change

    MiniMed completed its IPO. Medtronic retained about 90.03%, so Diabetes remained consolidated while separation progressed.

  27. Oct 7, 2026 · business change

    Medtronic decided to exit ventilator products, recording asset and inventory charges and retaining its remaining Acute Care and Monitoring business.

  28. Oct 7, 2026 · business change

    Medtronic signed an IP agreement with Edwards Lifesciences, receiving $265 million of one-time revenue plus future product royalties.

  29. Oct 7, 2026 · business change

    Medtronic contributed half of Renal Care Solutions to the Mozarc joint venture with DaVita, changing its consolidated product scope.

  30. Oct 7, 2026 · business change

    Medtronic sold Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses to Cardinal Health for $6.1 billion, reducing its mature supply portfolio.

  31. Oct 7, 2026 · analyst revision

    Added dated trajectories, management, testable bull and bear arguments, shared market links and current quality risks. Company-wide product integration is not treated as a third-party network effect.

  32. Oct 7, 2026 · analyst revision

    Replaced Q1 FY2027 revenue weights with FY2026 annual weights, removed segment profit weights that excluded group charges, and corrected the FY2026 filing date to June 18. Reclassified procedure training and internal product integration into training and workflow claims; added a limited Medical Surgical consumables claim from the new Hugo instrument clearance.

Industry & peers

Peer map

0%10%20%30%40%50%60708090100Moat scoreIndustry medianMDTABTZBHISRG

Hover a point for its values; click a peer to compare. Dashed lines: industry medians.

Global cardiovascular devices

As of Oct 8, 2026
OligopolyLow cyclicality

Rhythm management, cardiac ablation and mapping, heart-failure support, vascular intervention and structural-heart devices sold to hospitals and clinicians worldwide. Excludes diabetes devices, drugs, imaging and hospital procedure bills.

  1. Medtronic
  2. Abbott
  3. Boston Scientific
  4. Johnson & Johnson MedTech
  5. Edwards Lifesciences
2025 leaders, no comparable shares · MassDevice December 2025 cardiovascular special report
StocksMoatGross m.Op. m.
MDT5865.0%18.1%
Industry median147552.1%13.3%
Sector median557661.5%17.3%
All stocks median3987653.1%20.0%

Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.

Drivers & risks

Demand drivers
  • Aging and cardiovascular disease sustain demand for treatment. Access to trained clinicians limits how fast procedures can expand.
  • Pulsed field ablation, leadless pacing and transcatheter valves can expand eligible patients and change supplier share.
  • Hospital demand for shorter procedures and recovery can favor effective minimally invasive devices.
  • Successful trials, reimbursement and usable clinical workflows turn approvals into recurring procedure sales.
  • Reimbursement has a strong effect on newer treatment adoption. Procedure codes and regulatory clearance need payer coverage and trained staff before demand turns into sales.
Risks
  • Large rivals can displace products with better clinical results, procedure speed or safety; a broad patent portfolio does not establish exclusivity.
  • Hospital purchasing groups and reimbursement controls cap realized prices.
  • High rates and constrained hospital budgets can delay capital systems; clinician shortages can restrict procedures even when patient demand is strong.
  • Tariffs, manufacturing problems, recalls and regulatory requirements raise costs or interrupt supply. Currency translation affects global manufacturers.
  • Remote monitoring and mapping software can contain clinically relevant errors. Installed workflows require reliable updates and support; integration alone does not ensure retention.

Bulls & bears

Key question · as of Nov 11, 2026

Can Medtronic turn ablation, connected spine systems and new procedure platforms into durable sales and cash earnings after MiniMed separates, while keeping quality costs and hospital price pressure under control?

Arguments

4 forFaded: weakening or settled6 against

What to watch

  1. 1Cardiac Ablation Solutions sales and reported competitive share movement
  2. 2Cranial and Spinal Technologies sales, navigation placements and implant pull-through
  3. 3Hugo installed systems, procedures and instrument sales
  4. 4Actual post-exchange shares and issuer-recast continuing earnings
  5. 5Recall remediation, product availability and litigation costs
  6. 6Reported operating cash flow, capex and recurring restructuring

Next check: Q2 FY2027 results on November 24: review the continuing-operation recast after MiniMed, actual post-exchange shares, separation taxes and cash costs, then ablation and surgical-platform growth.

Sources: company filings and dated sources collected for Find My Moat; Post-separation shares outstanding have not been verified; market cap and valuation multiples are unavailable. Not investment advice.

Cite or reuse this data

Free to reuse, commercially too, with a credit link. See the data license.

Moat Score 58/100 by <a href="https://www.findmymoat.com/stocks/XNYS:MDT">Find My Moat</a> (as of September 2026)

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.